Androgen receptor antagonism and impact on inhibitors of androgen synthesis in prostate cancer therapy

Vincent C. O. Njar


In a recent article by Norris and colleagues, published in high-impact J Clin Invest (1), the authors investigated the potential role of androgen receptor (AR) antagonism and the efficacy of cytochrome P450 17A1 (hereafter called CYP17) inhibitors in prostate cancer models.